Overview

• A Cell Metabolics study at the University of Utah found that Ozempic-induced weight loss in mice reduced lean body mass by about 10%, largely from non-skeletal tissues such as the liver
• Despite minimal atrophy, strength tests revealed that some skeletal muscles weakened as mice lost weight, raising functional and longevity concerns
• Investigators caution that differences in metabolism between species require urgent human clinical trials to determine whether similar muscle losses occur in people
• A review by University of Virginia experts highlights that GLP-1 therapies may compromise cardiorespiratory fitness, potentially elevating risks of cardiovascular disease, mortality and diminished quality of life
• To counteract potential muscle decline, specialists urge incorporation of structured exercise regimens, targeted nutritional support alongside adjunct therapies, especially for adults over 60